Nasdaq:KLTO
Klotho Neurosciences, Inc.
A pre-revenue biotech firm targeting neurological conditions with substantial R&D investments funded by financing inflows.
Key Metrics
Investment Thesis
Bull Case
Investors may buy based on the potential for a breakthrough therapy in the lucrative neurological disorder market if clinical trials succeed. The recent $3.1M cash flow from financing extends the company's runway, allowing it to continue its R&D pipeline without immediate commercialization pressure. If any clinical candidates receive approval, the transition to revenue could be exponential given the high unmet medical need.
Bear Case
The stock is highly speculative with no current product sales and a significant retained earnings deficit of -$10.6M. The negative net income trend from $1.3M in 2023 to -$6.2M in 2024 suggests deteriorating financial health or inefficient capital allocation. High operating expenses relative to zero revenue create a fragile balance sheet with current liabilities exceeding current assets.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. is a biotechnology company developing novel therapies for neurological disorders, primarily focusing on the Central Nervous System markets. The company leverages its proprietary platform to address unmet needs in neurodegenerative diseases and pain management. Key financial indicators show significant cash burn with zero revenue, typical of early-stage clinical development firms.
Analysis
Management Discussion
The company reported a net profit of -$6.2M in 2024, marking a sharp decline from profits in 2022 and 2023, indicating aggressive spending or one-time charges. Operating expenses surged to $5.5M while revenue remained at zero, resulting in an operating profit of -$5.5M. Despite cash flow from operations being negative at -$2.9M, the company managed to increase its cash position slightly through financing activities of $3.1M.
Industry Overview
The neurological disorder treatment industry is growing rapidly due to an aging population and advances in understanding brain diseases. Companies often require billions in R&D before generating sales, leading to volatile stock prices based on trial results. Success depends heavily on regulatory approvals and the ability to secure strategic partnerships or IPO status.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $657.0K | $1.3M | $5.5M |
| Operating Income | $-657.0K | $-1.3M | $-5.5M |
| R&D | — | — | $0 |
| G&A | $534.0K | $1.2M | $129.4K |
| Stock-Based Comp | — | — | $2.6M |
| Other OpEx | $123.0K | $75.6K | $5.4M |
| Non-Operating Income | $0 | $3.3M | $-610.1K |
| Interest Income | $1.3M | $3.4M | — |
| Pre-Tax Income | $-657.0K | $2.0M | $-6.2M |
| Income Tax | $243.1K | $690.6K | $0 |
| Continuing Ops | $-900.1K | $1.3M | $-6.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.2M | $1.3M | $-6.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $1.2M | $1.3M | $-6.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $440.2K | $199.5K | $157.8K |
| Cash & Equivalents | — | $172.5K | $63.7K |
| Other Current Assets | — | $27.0K | $94.1K |
| Long-Term Assets | $117.8M | $19.3M | $2.3M |
| Total Assets | $118.2M | $19.5M | $2.5M |
| Current Liabilities | $506.2K | $2.3M | $1.2M |
| Accounts Payable | — | — | $63.7K |
| Other Current Liab | $365.9K | $1.9M | $271.8K |
| Long-Term Liabilities | $4.4M | $5.9M | $24.5K |
| Total Liabilities | $4.9M | $8.2M | $1.3M |
| Shareholders' Equity | $113.3M | $11.2M | $1.2M |
| Paid-In Capital | — | — | $11.7M |
| Retained Earnings | $-4.0M | $-7.4M | $-10.6M |
| Total L&E | $118.2M | $19.5M | $2.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $1.2M | $1.3M | $-6.2M |
| Non-Cash Adjustments | $-1.8M | $-3.4M | $2.9M |
| Working Capital Changes | $49.5K | $753.6K | $331.0K |
| Cash from Operations | $-493.0K | $-1.3M | $-2.9M |
| Cash from Investing | $-116.2M | $101.9M | $-123.5K |
| Cash from Financing | $117.0M | $-100.8M | $3.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $336.0K | $-168.4K | $60.9K |
| Beginning Cash | $5.0K | $341.0K | $2.8K |
| Ending Cash | $341.0K | $172.5K | $63.7K |
Frequently Asked Questions
How does Klotho Neurosciences, Inc. make money?
Neuroscience Drug Development: Focus on CNS indications including Alzheimer's, Parkinson's, and pain. Strategic Partnerships: Licensing or collaboration deals to offset high development costs. Intellectual Property Portfolio: Patents covering novel mechanisms of action for neurotherapeutics.
What are the main risks for KLTO?
Zero Revenue and Cash Burn: The company reports $0 revenue and a net loss of $6.2M, relying entirely on external capital. Regulatory Uncertainty: Success depends on FDA approval timelines for clinical candidates which are unpredictable. Dilution Risk: Ongoing cash flow needs from financing may lead to significant equity dilution for existing shareholders.
What is KLTO's competitive advantage?
Proprietary Target Discovery Platform: Unique ability to identify new therapeutic targets in the central nervous system. Experienced Management Team: Leadership with deep expertise in neuroscience and drug development from top-tier institutions. Strategic Financing Capability: Recent $3.1M cash flow from financing provides runway for continued research without immediate revenue pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.